Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Capital Expenditures data on file, last reported at $1.0 million in Q1 2026.

• On a quarterly basis, Capital Expenditures changed 0.0% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 59.24% decrease from a year earlier, with the FY2025 full-year figure at $6.0 million, down 60.0% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.0 million, up from $938000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for RARE reached as high as $95.7 million in Q4 2022 and fell as low as -$42.7 million in Q3 2022.
• Historically, Capital Expenditures has averaged $8.7 million across 5 years, with a median of $2.8 million in 2025.
• Across the five-year window, Capital Expenditures slumped 307.55% in 2022 and surged 830.71% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $95.7 million in 2022, then slumped by 134.14% to -$32.7 million in 2023, then jumped by 124.99% to $8.2 million in 2024, then tumbled by 88.51% to $938000.0 in 2025, then increased by 6.61% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1.0 million in Q1 2026, $938000.0 in Q4 2025, and $1.3 million in Q3 2025.